Dynavax Technologies - Stock Price History | DVAX

Historical daily share price chart and data for Dynavax Technologies since 2021 adjusted for splits. The latest closing stock price for Dynavax Technologies as of October 27, 2021 is 19.70.
  • The all-time high Dynavax Technologies stock closing price was 98.50 on December 11, 2006.
  • The Dynavax Technologies 52-week high stock price is 20.96, which is 6.4% above the current share price.
  • The Dynavax Technologies 52-week low stock price is 3.58, which is 81.8% below the current share price.
  • The average Dynavax Technologies stock price for the last 52 weeks is 9.83.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Dynavax Technologies Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 5.3443 5.4700 11.7000 2.2700 4.4500 -22.20%
2019 6.1580 9.4500 12.0900 2.6900 5.7200 -37.49%
2018 14.7785 18.8000 20.7500 8.1400 9.1500 -51.07%
2017 11.8018 4.0500 24.0750 3.8000 18.7000 373.42%
2016 14.7131 23.1500 29.7000 3.9000 3.9500 -83.65%
2015 23.6379 17.4100 31.6800 16.0000 24.1600 43.30%
2014 15.7874 19.9000 20.7000 13.0000 16.8600 -13.98%
2013 18.6199 29.2000 33.3000 10.1000 19.6000 -31.23%
2012 40.2482 32.8000 52.6000 24.4000 28.5000 -14.16%
2011 27.1563 30.9000 35.3000 18.2000 33.2000 3.75%
2010 18.1281 14.4000 32.0000 12.7000 32.0000 125.35%
2009 12.5715 7.8990 25.5000 5.1000 14.2000 69.05%
2008 22.2934 52.5000 65.5000 1.5100 8.4000 -83.56%
2007 48.6636 84.7000 87.9000 36.7000 51.1000 -44.34%
2006 55.9188 42.9000 98.5000 36.4000 91.8000 118.05%
2005 53.6628 77.9000 79.9000 35.9000 42.1000 -47.38%
2004 66.9763 94.0000 94.0000 41.8000 80.0000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.201B $0.047B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86